Skip to main content
OpenTrials
Completed

NCT Number: NCT01738373

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bone Marrow / Autologous Transplants Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Marseille, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012
  • Patients who have been informed and who have given their written consent for the access to their medical file

Exclusion criteria

  • Patients already included in a Plerixafor ongoing clinical trial.

Treatment and study plan

plerixafor

Drug

Plerixafor will be prescribed independently by the physician, according to usual practice.

Other names: Mozobil®

Primary outcomes

  1. The characteristics of the patients who received treatment

    Time frame: 13 months

  2. Dosage of treatment

    Time frame: 13 months

  3. Number of CD34+ cells collected following treatment

    Time frame: 13 months

  4. Number of patients with the existence of one or more predictive factors of poor mobilisation

    Time frame: 13 months

  5. Duration of treatment

    Time frame: 13 months

  6. Associated treatments

    Time frame: 13 months

Sponsors and collaborators

Lead sponsor

Genzyme, a Sanofi Company

Industry

Registry information

Official study title

Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Nov 30, 2012
Registry last updated
Mar 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.